Evidence map›Paper›PMID 40565013›Full record

ReviewInternational journal of molecular sciences2025

Plant Metabolites as Potential Agents That Potentiate or Block Resistance Mechanisms Involving β-Lactamases and Efflux Pumps.

Muhammad Jawad Zai, Ian Edwin Cock, Matthew James Cheesman

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Pharmaceuticals (Basel, Switzerland) · 2025
    Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Muhammad Jawad ZaiCentre for Planetary Health and Food Security, Griffith University, Brisbane, QLD 4111, Australia.ORCID 0009-0008-1965-6604
Ian Edwin CockCentre for Planetary Health and Food Security, Griffith University, Brisbane, QLD 4111, Australia.ORCID 0000-0002-8732-8513
Matthew James CheesmanSchool of Pharmacy and Medical Sciences, Griffith University, Southport, QLD 4222, Australia.ORCID 0000-0002-2306-0829

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The dramatic increase in antimicrobial resistance (AMR) in recent decades has created an urgent need to develop new antimicrobial agents and compounds that can modify and/or block bacterial resistance mechanisms. An understanding of these resistance mechanisms and how to overcome them would substantially assist in the development of new antibiotic chemotherapies. Bacteria may develop AMR through multiple differing mechanisms, including modification of the antibiotic target site, limitation of antibiotic uptake, active efflux of the antibiotic, and via direct modification and inactivation of the antibiotic. Of these, efflux pumps and the production of β-lactamases are the most common resistance mechanisms that render antibiotics inactive. The development of resistance-modifying agents (particularly those targeting efflux pumps and β-lactamase enzymes) is an important consideration to counteract the spread of AMR. This strategy may repurpose existing antibiotics by blocking bacterial resistance mechanisms, thereby increasing the efficacy of the antibiotic compounds. This review focuses on known phytochemicals that possess efflux pump inhibitory and/or β-lactamase inhibitory activities. The interaction of phytochemicals possessing efflux pumps and/or β-lactamase inhibitory activities in combination with clinical antibiotics is also discussed. Additionally, the challenges associated with further development of these phytochemicals as potentiating agents is discussed to highlight their therapeutic potential, and to guide future research.

Indexed as

Anti-Bacterial AgentsBacteriabeta-Lactamase Inhibitorsbeta-LactamasesDrug Resistance, BacterialMembrane Transport ProteinsPhytochemicalsPlantsHumansAnti-Bacterial Agentsbeta-Lactamase Inhibitorsbeta-LactamasesMembrane Transport ProteinsPhytochemicalsantibiotic potentiationantibiotic resistancecombinational therapiesefflux pump inhibitorphytochemicalsβ-lactamase inhibitor

Identifiers

PMID40565013
PMCPMC12192949

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.